BACKGROUND: The StratifyJCV® test is a qualitative assay to classify MS patients as anti-JC virus (JCV) antibody positive or negative. Quantification of anti-JCV antibody levels in serum and cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients might add to the progressive multifocal leukoencephalopathy (PML) risk assessment. OBJECTIVE: The objective of this study is to test sera of patients in a quantitative anti-JCV antibody assay, and to compare the results with preexisting data from the StratifyJCV® test. METHODS: Sera of a total of 175 MS patients and matched non-MS-controls were tested for anti-JCV antibodies using glutathione S-transferase-tagged-VP1 as antigen. Antibody reactivity was quantified in arbitrary units using human immunoglobulin as standard. RESULTS: The comparison of our assay with StratifyJCV® showed good inter-assay agreement (kappa 0.6), and strong correlation for antibody reactivity (r (2) = 0.94). Discordant samples had low-reactive positivity, and a higher proportion (13% vs. 4%) tested positive in the StratifyJCV® test only. CONCLUSIONS: The method presented is a tool for the reliable quantification of anti-JCV antibodies, which demonstrates good agreement with results from StratifyJCV®. In contrast to StratifyJCV®, we pre-adsorbed all of the sera with BK virus (BKV) VP1 protein to reduce cross-reactivity. This step may account for a higher species-specificity of our assay. As such, our assay might be a promising additional tool for PML risk assessment.
BACKGROUND: The StratifyJCV® test is a qualitative assay to classify MSpatients as anti-JC virus (JCV) antibody positive or negative. Quantification of anti-JCV antibody levels in serum and cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients might add to the progressive multifocal leukoencephalopathy (PML) risk assessment. OBJECTIVE: The objective of this study is to test sera of patients in a quantitative anti-JCV antibody assay, and to compare the results with preexisting data from the StratifyJCV® test. METHODS: Sera of a total of 175 MSpatients and matched non-MS-controls were tested for anti-JCV antibodies using glutathione S-transferase-tagged-VP1 as antigen. Antibody reactivity was quantified in arbitrary units using human immunoglobulin as standard. RESULTS: The comparison of our assay with StratifyJCV® showed good inter-assay agreement (kappa 0.6), and strong correlation for antibody reactivity (r (2) = 0.94). Discordant samples had low-reactive positivity, and a higher proportion (13% vs. 4%) tested positive in the StratifyJCV® test only. CONCLUSIONS: The method presented is a tool for the reliable quantification of anti-JCV antibodies, which demonstrates good agreement with results from StratifyJCV®. In contrast to StratifyJCV®, we pre-adsorbed all of the sera with BK virus (BKV) VP1 protein to reduce cross-reactivity. This step may account for a higher species-specificity of our assay. As such, our assay might be a promising additional tool for PML risk assessment.
Authors: Su-Hyun Kim; Jae-Won Hyun; In Hye Jeong; AeRan Joung; Joung-Lim Yeon; Thomas Dehmel; Ortwin Adams; Bernd C Kieseier; Ho Jin Kim Journal: J Neurol Date: 2015-01-06 Impact factor: 4.849
Authors: Jens Verheyen; Kseniya Maizus; Eugen Feist; Zebulon Tolman; Elena Knops; Jasemine Saech; Lydia Spengler; Tim Waterboer; Gerd R Burmester; Michael Pawlita; Herbert Pfister; Andrea Rubbert-Roth Journal: Med Microbiol Immunol Date: 2015-02-13 Impact factor: 3.402
Authors: Clemens Warnke; Gloria von Geldern; Philipp Markwerth; Thomas Dehmel; Robert Hoepner; Ralf Gold; Michael Pawlita; Tania Kümpfel; Mathias Mäurer; Martin Stangel; Florian Wegner; Reinhard Hohlfeld; Vera Straeten; Volker Limmroth; Thomas Weber; Derik Hermsen; Christoph Kleinschnitz; Hans-Peter Hartung; Mike P Wattjes; Anders Svenningson; Eugene Major; Tomas Olsson; Bernd C Kieseier; Ortwin Adams Journal: Ann Neurol Date: 2014-05-08 Impact factor: 10.422
Authors: Emilie Sundqvist; Dorothea Buck; Clemens Warnke; Eva Albrecht; Christian Gieger; Mohsen Khademi; Izaura Lima Bomfim; Anna Fogdell-Hahn; Jenny Link; Lars Alfredsson; Helle Bach Søndergaard; Jan Hillert; Annette B Oturai; Bernhard Hemmer; Bernhard Hemme; Ingrid Kockum; Tomas Olsson Journal: PLoS Pathog Date: 2014-04-24 Impact factor: 6.823
Authors: Yi Luo; Nora Möhn; Amani Al-Mekhlafi; Sven Schuchardt; Thomas Skripuletz; Wolfram Sühs; Frank Pessler; Martin Stangel Journal: PLoS One Date: 2020-11-24 Impact factor: 3.240
Authors: Ortwin Adams; Marcel Andrée; Denise Rabl; Philipp N Ostermann; Heiner Schaal; Erik Lehnert; Stefanie Ackerstaff; Lisa Müller; Johannes C Fischer Journal: J Med Virol Date: 2021-11-08 Impact factor: 20.693